NutraBrain Clinic

Ketamine telehealth at NutraBrain: 8 steps across 15 states

UNITED STATES – November 14, 2026 -- Ketamine telehealth at NutraBrain Clinic takes roughly 8 to 12 days from intake to medication at your door, by our calculation, and includes one video call of about 30 minutes with the prescribing physician. The clinic, led by anesthesiologist Dr. David Mahjoubi, has published its eight-step process for at-home treatment in 15 U.S. states. Ongoing membership costs $69 a month.

Dr. Mahjoubi says he sees every patient by video before prescribing

The clinic says this is not standard in the industry, where many programs use rotating nurse practitioners. Mahjoubi is an anesthesiologist, not a psychiatrist. He recommends patients keep their existing psychiatrist.

Before the call, you complete two screens:

NutraBrain at-home ketamine for chronic pain costs $425, then $69

UNITED STATES – November 14, 2026 -- Chronic pain patients in 15 US states can get ketamine therapy delivered to their door for $425 in the first month and $69 a month after that. NutraBrain Clinic, a telehealth provider, says it ships the medication by mail once its medical director, Dr. David Mahjoubi, has assessed a patient by video.

The price is for the clinic's Monthly Care plan. The first month covers the consultation and the medication. From month two, $69 a month covers ongoing care, including additional consultations and prescription adjustments. The monthly fee drops by $356 after the first month. Over 12 months, the listed prices add up to $1,184 ($425 plus 11 × $69), by our calculation.

The company has not said whether the $69 also covers medication after the first prescription, which NutraBrain pays for on Monthly Care.

Ketamine study finds immune link, but no response test exists yet

GLOBAL — October 20, 2026 -- No blood test can tell you today whether ketamine will work for your depression. A 2026 Molecular Psychiatry study by Jones GH, Gilbert JR, Johnston JN and colleagues points to immune markers that may one day help.

The team compared four compounds: ketamine, its metabolite hydroxynorketamine (HNK), LSD and psilocybin. Ketamine blocks NMDA receptors in the glutamate system. LSD and psilocybin act mainly on serotonin receptors. The question was whether drugs that start in different places end up changing the same things inside neurons.